sGC β2 Inhibitors

Chemical inhibitors of soluble guanylate cyclase (sGC) β2 utilize various mechanisms to affect the protein's function. ODQ acts by oxidizing the heme group within the enzyme, which is essential for its catalytic activity in synthesizing cyclic guanosine monophosphate (cGMP). This chemical effectively prevents sGC β2 from fulfilling its role in cGMP production. Similarly, NS2028 exerts its inhibitory effect by binding to the heme domain of sGC β2 and obstructing the activation by nitric oxide (NO), which is crucial for the enzyme to convert guanosine triphosphate (GTP) to cGMP. Methylene Blue competes with NO at the heme binding site of sGC β2, directly inhibiting the enzyme's activation and subsequent cGMP synthesis. LY83583 induces the generation of reactive oxygen species, which oxidize the heme group of sGC β2, decreasing the enzyme's ability to be activated by NO. YC-1 is another inhibitor that directly binds to sGC β2 and suppresses its activity even in the presence of NO, thus reducing cGMP production.

Additionally, several inhibitors affect sGC β2 activity indirectly by targeting pathways related to the enzyme's function. Rp-8-Br-PET-cGMPS and Rp-8-pCPT-cGMPS are competitive inhibitors of cGMP-dependent protein kinases, which are the downstream effectors of sGC β2 signaling. By inhibiting these kinases, the compounds indirectly reduce the physiological actions initiated by sGC β2. S-Methylisothiourea and L-NAME both inhibit nitric oxide synthase, resulting in decreased NO production, which is necessary for the activation of sGC β2. Consequently, the activity of sGC β2 is indirectly diminished. LY294002 inhibits phosphoinositide 3-kinase (PI3K), leading to lowered NO synthesis and thus reduced sGC β2 activation. C-PTIO, a NO scavenger, decreases the availability of NO required for sGC β2 activation, leading to a decline in its mediated cGMP production. Methyl Blue also competes with nitric oxide at the heme binding site on sGC β2, thereby directly inhibiting the enzyme's function.